POSTER BOOKLET

Download your booklet

Microphysiological System for Studying Fatty Liver Disease and its Impact on Drug-Induced Liver Injury

Overview:

As a result of the increased prevalence of diabetes, obesity and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed country (1). NAFLD is a spectrum of pathologies ranging from benign hepatic steatosis through to non-alcoholic steatohepatitis (NASH), which can ultimately lead to cirrhosis and liver cancer. There are currently no FDA approved drugs for the treatment of NAFLD/NASH and there is a clear requirement for better models to understand this disease.

Authors
cnb-1
Tomasz Kostrzewski, Alina Miedzik, David Hughes

CN Bio, Cambridge, UK

gsk-1
Sophie Reagen, Abhishek Srivvastava, Dominic Williams

AstraZeneca, Cambridge, UK